Auris Medical to Provide Business Update on AM-301 Program on Tuesday, April 13, 2021
Auris Medical Holding Ltd. (NASDAQ: EARS) is set to provide a business update on its AM-301 program, which focuses on protection against airborne viruses and allergens, on April 13, 2021. The event will include a conference call and webcast starting at 8:00 am Eastern Time. This follows the company’s ongoing work in developing intranasal therapeutics for various medical needs, with several programs in different developmental phases, including AM-125 for vertigo and AM-111 for acute inner ear hearing loss.
- Upcoming business update on AM-301 program, enhancing investor engagement.
- Multiple therapeutic programs in development, indicating a diversified pipeline.
- None.
Hamilton, Bermuda, April 8, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today announced that it will provide a business update on its AM-301 program for protection against airborne viruses and allergens on Tuesday, April 13, 2021. Following the announcement, Auris Medical's management team will host a live conference call and webcast at 8:00 am Eastern Time (2:00 pm Central European Time).
To participate in this conference call, dial +1-877-870-9135 (US, toll free) or +44-2071-928-338 (international), and enter passcode 5649276. A live webcast of the conference call can be accessed in the Investor Relations section of the Auris Medical website at www.aurismedical.com. A replay will be available approximately two hours following the live call.
About Auris Medical
Auris Medical is a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders. The Company is focused on the development of intranasal betahistine for the treatment of vertigo (AM-125, in Phase 2) and for the prevention of antipsychotic-induced weight gain and somnolence (AM-201, post Phase 1b). Through its affiliate Altamira Medica, the Company is developing a nasal spray for protection against airborne viruses and allergens (AM-301). In addition, Auris Medical has two Phase 3 programs under development: Sonsuvi® (AM-111) for acute inner ear hearing loss and Keyzilen® (AM-101) for acute inner ear tinnitus. The Company was founded in 2003 and is headquartered in Hamilton, Bermuda with its main operations in Basel, Switzerland. The shares of Auris Medical Holding Ltd. trade on the NASDAQ Capital Market under the symbol “EARS.”
Investor contact:
FAQ
What is Auris Medical's AM-301 program about?
When will Auris Medical hold the business update conference call?
What are the main products in development by Auris Medical?
What stock symbol does Auris Medical trade under?
